These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2537 related items for PubMed ID: 21107323

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma.
    Yadav V, Zhang X, Liu J, Estrem S, Li S, Gong XQ, Buchanan S, Henry JR, Starling JJ, Peng SB.
    J Biol Chem; 2012 Aug 10; 287(33):28087-98. PubMed ID: 22730329
    [Abstract] [Full Text] [Related]

  • 3. Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition.
    Shi H, Kong X, Ribas A, Lo RS.
    Cancer Res; 2011 Aug 01; 71(15):5067-74. PubMed ID: 21803746
    [Abstract] [Full Text] [Related]

  • 4. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.
    Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, Caponigro G, Hieronymus H, Murray RR, Salehi-Ashtiani K, Hill DE, Vidal M, Zhao JJ, Yang X, Alkan O, Kim S, Harris JL, Wilson CJ, Myer VE, Finan PM, Root DE, Roberts TM, Golub T, Flaherty KT, Dummer R, Weber BL, Sellers WR, Schlegel R, Wargo JA, Hahn WC, Garraway LA.
    Nature; 2010 Dec 16; 468(7326):968-72. PubMed ID: 21107320
    [Abstract] [Full Text] [Related]

  • 5. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).
    Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, Shi H, Atefi M, Titz B, Gabay MT, Salton M, Dahlman KB, Tadi M, Wargo JA, Flaherty KT, Kelley MC, Misteli T, Chapman PB, Sosman JA, Graeber TG, Ribas A, Lo RS, Rosen N, Solit DB.
    Nature; 2011 Nov 23; 480(7377):387-90. PubMed ID: 22113612
    [Abstract] [Full Text] [Related]

  • 6. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
    Jenkins MH, Croteau W, Mullins DW, Brinckerhoff CE.
    Matrix Biol; 2015 Oct 23; 48():66-77. PubMed ID: 25989506
    [Abstract] [Full Text] [Related]

  • 7. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.
    Sun C, Wang L, Huang S, Heynen GJ, Prahallad A, Robert C, Haanen J, Blank C, Wesseling J, Willems SM, Zecchin D, Hobor S, Bajpe PK, Lieftink C, Mateus C, Vagner S, Grernrum W, Hofland I, Schlicker A, Wessels LF, Beijersbergen RL, Bardelli A, Di Nicolantonio F, Eggermont AM, Bernards R.
    Nature; 2014 Apr 03; 508(7494):118-22. PubMed ID: 24670642
    [Abstract] [Full Text] [Related]

  • 8. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner.
    Joseph EW, Pratilas CA, Poulikakos PI, Tadi M, Wang W, Taylor BS, Halilovic E, Persaud Y, Xing F, Viale A, Tsai J, Chapman PB, Bollag G, Solit DB, Rosen N.
    Proc Natl Acad Sci U S A; 2010 Aug 17; 107(33):14903-8. PubMed ID: 20668238
    [Abstract] [Full Text] [Related]

  • 9. Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.
    Atefi M, von Euw E, Attar N, Ng C, Chu C, Guo D, Nazarian R, Chmielowski B, Glaspy JA, Comin-Anduix B, Mischel PS, Lo RS, Ribas A.
    PLoS One; 2011 Aug 17; 6(12):e28973. PubMed ID: 22194965
    [Abstract] [Full Text] [Related]

  • 10. Mitogen-activated protein kinase (MAPK) hyperactivation and enhanced NRAS expression drive acquired vemurafenib resistance in V600E BRAF melanoma cells.
    Lidsky M, Antoun G, Speicher P, Adams B, Turley R, Augustine C, Tyler D, Ali-Osman F.
    J Biol Chem; 2014 Oct 03; 289(40):27714-26. PubMed ID: 25063807
    [Abstract] [Full Text] [Related]

  • 11. Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation.
    Su F, Bradley WD, Wang Q, Yang H, Xu L, Higgins B, Kolinsky K, Packman K, Kim MJ, Trunzer K, Lee RJ, Schostack K, Carter J, Albert T, Germer S, Rosinski J, Martin M, Simcox ME, Lestini B, Heimbrook D, Bollag G.
    Cancer Res; 2012 Feb 15; 72(4):969-78. PubMed ID: 22205714
    [Abstract] [Full Text] [Related]

  • 12. Hepatocyte growth factor renders BRAF mutant human melanoma cell lines resistant to PLX4032 by downregulating the pro-apoptotic BH3-only proteins PUMA and BIM.
    Rohrbeck L, Gong JN, Lee EF, Kueh AJ, Behren A, Tai L, Lessene G, Huang DC, Fairlie WD, Strasser A, Herold MJ.
    Cell Death Differ; 2016 Dec 15; 23(12):2054-2062. PubMed ID: 27689874
    [Abstract] [Full Text] [Related]

  • 13. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
    Acquaviva J, Smith DL, Jimenez JP, Zhang C, Sequeira M, He S, Sang J, Bates RC, Proia DA.
    Mol Cancer Ther; 2014 Feb 15; 13(2):353-63. PubMed ID: 24398428
    [Abstract] [Full Text] [Related]

  • 14. p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib.
    Krayem M, Journe F, Wiedig M, Morandini R, Najem A, Salès F, van Kempen LC, Sibille C, Awada A, Marine JC, Ghanem G.
    Eur J Cancer; 2016 Mar 15; 55():98-110. PubMed ID: 26790143
    [Abstract] [Full Text] [Related]

  • 15. Drug discovery: How melanomas bypass new therapy.
    Solit D, Sawyers CL.
    Nature; 2010 Dec 16; 468(7326):902-3. PubMed ID: 21164474
    [No Abstract] [Full Text] [Related]

  • 16. Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors.
    Basile KJ, Le K, Hartsough EJ, Aplin AE.
    Pigment Cell Melanoma Res; 2014 May 16; 27(3):479-84. PubMed ID: 24422853
    [Abstract] [Full Text] [Related]

  • 17. Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma.
    Tap WD, Gong KW, Dering J, Tseng Y, Ginther C, Pauletti G, Glaspy JA, Essner R, Bollag G, Hirth P, Zhang C, Slamon DJ.
    Neoplasia; 2010 Aug 16; 12(8):637-49. PubMed ID: 20689758
    [Abstract] [Full Text] [Related]

  • 18. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.
    Okimoto RA, Lin L, Olivas V, Chan E, Markegard E, Rymar A, Neel D, Chen X, Hemmati G, Bollag G, Bivona TG.
    Proc Natl Acad Sci U S A; 2016 Nov 22; 113(47):13456-13461. PubMed ID: 27834212
    [Abstract] [Full Text] [Related]

  • 19. Adaptive upregulation of FOXD3 and resistance to PLX4032/4720-induced cell death in mutant B-RAF melanoma cells.
    Basile KJ, Abel EV, Aplin AE.
    Oncogene; 2012 May 10; 31(19):2471-9. PubMed ID: 21996740
    [Abstract] [Full Text] [Related]

  • 20. Mechanisms of resistance to RAF inhibition in melanomas harboring a BRAF mutation.
    Chapman PB.
    Am Soc Clin Oncol Educ Book; 2013 May 10. PubMed ID: 23714462
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 127.